DOI: 10.1161/circ.148.suppl_1.16546 ISSN: 0009-7322

Abstract 16546: Impact of Hyperuricemia on 5-year Clinical Outcomes in Patients With Percutaneous Transluminal Angioplasty

Seung-Woon Rha, Woo Jin Ahn, Seong Joon An, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jinah Cha, Sujin Hyun, Soohyung Park, Dong Oh O Kang, Eun Jin J Park, Cheol Ung Choi
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Background: Although the correlation between hyperuricemia and cardiovascular disease (CVD) is well known, there have been limited data regarding the impact of hyperuricemia on long-term clinical outcomes in patients with peripheral arterial disease (PAD) after percutaneous transluminal angioplasty (PTA).

Methods: A total of 943 patients who underwent PTA for PAD were enrolled. The patients were divided into the hyperuricemia group (N=168) and the normal group (N=550). Hyperuricemia was defined as a uric acid level ≥7.0 mg/dL in men, and ≥6.5 mg/dL in women. The primary endpoint was major adverse cerebral and cardiovascular event (MACCE), including death, myocardial infarction (MI), any coronary revascularization and stroke, up to 5 years. The secondary endpoint was major adverse limb event (MALE), including any repeated PTA, and target extremity surgery (TES). In addition, inverse probability weighting (IPTW) analysis, derived from the logistic regression model, was performed to adjust potential confounders.

Results: After IPTW matching analysis, compared to the normal group, the hyperuricemia group was not associated with MACCE but associated with an increased incidence of MI (2.6% vs. 0.5%, p = 0.001), and coronary revascularization (6.7% vs. 3.9%, p = 0.018). Also, the hyperuricemia group was associated with higher incidence of MALE (45.3% vs. 28.9%, p < 0.001), including a target extremity revascularization (TER; 25.1% vs. 15.9%, p < 0.001), non-TER (11.5% vs. 5.6%, p < 0.001), and TES (22.8% vs. 16.2%, p = 0.002).

Conclusions: In the present study, hyperuricemia was associated with worse clinical outcomes during 5-year clinical follow-up. Further investigations should be made regarding the clinical benefit of controlling hyperuricemia on clinical outcomes.

More from our Archive